Insmed
INSM
101.74
-3.49
-3.32%
Insmed
US · INSM
#794 by market cap
Listed 1970
101.74
-3.49
-3.32%
Live - 5344 symbols - heartbeat 337s ago
· 2026-10-08 08:22
Pre-market
101.20
-0.53%
After-hours
103.00
+1.23%
Overnight
101.99
+0.25%
- Market cap
- 22.22B
- P/E (TTM)i
- -24.69
- P/Bi
- 29.33
- EPSi
- -6.42
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on INSM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.77, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +66.73% YoY
Margins
- Gross margin
- 79.73%
- Operating margin
- -164.04%
- Net margin
- -210.54%
Key ratios & quality
- Enterprise valuei
- 21.34B
- Altman Z-Scorei
- 4.77
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.84M | 136.47M | 164.41M | 188.46M | 245.36M | 305.21M | 363.71M | 606.42M |
| Gross profit | 7.41M | 112.26M | 124.54M | 144.31M | 190.23M | 239.64M | 277.97M | 483.49M |
| Selling & admin expenses | 168.22M | 210.80M | 203.61M | 234.27M | 265.78M | 344.50M | 461.12M | 701.17M |
| Research & development | 145.28M | 131.71M | 181.16M | 272.74M | 397.52M | 571.01M | 598.37M | 771.09M |
| Operating profit | -307.34M | -235.25M | -265.23M | -367.76M | -478.12M | -680.93M | -786.57M | -994.78M |
| Pretax profit | -324.08M | -253.56M | -292.69M | -436.41M | -480.15M | -747.01M | -910.07M | -1.27B |
| Tax | 201.00K | 777.00K | 1.40M | -1.76M | 1.38M | 2.56M | 3.71M | 5.03M |
| Net profit | -324.28M | -254.34M | -294.09M | -434.65M | -481.53M | -749.57M | -913.77M | -1.28B |
| Basic EPS | -4 | -3 | -3 | -4 | -4 | -5 | -6 | -6 |
| Diluted EPS | -4.22 | -3.01 | -3.01 | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 92.82M | 107.42M | 142.34M | 263.84M | 305.96M | 425.49M |
| Gross profit | 71.55M | 79.34M | 112.98M | 219.62M | 258.54M | 358.27M |
| Selling & admin expenses | 147.55M | 154.76M | 186.38M | 212.48M | 247.26M | 247.47M |
| Research & development | 152.58M | 177.19M | 186.42M | 254.91M | 209.49M | 210.03M |
| Operating profit | -229.84M | -253.88M | -261.35M | -249.71M | -200.28M | -101.31M |
| Pretax profit | -255.67M | -320.44M | -368.70M | -326.93M | -162.10M | -11.37M |
| Tax | 912.00K | 1.24M | 1.32M | 1.55M | 1.47M | 1.87M |
| Net profit | -256.58M | -321.69M | -370.02M | -328.49M | -163.56M | -13.24M |
| Basic EPS | -1 | -2 | -2 | -2 | -1 | 0 |
| Diluted EPS | -1.42 | -1.70 | -1.75 | -1.54 | -0.76 | -0.06 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 518.95M | 555.19M | 622.89M | 837.04M | 1.27B | 929.06M | 1.62B | 1.79B |
| Cash & ST investments | 495.07M | 487.43M | 532.76M | 716.78M | 1.15B | 780.45M | 1.43B | 1.43B |
| Inventory | 7.03M | 28.31M | 49.59M | 67.01M | 69.92M | 83.25M | 98.58M | 132.07M |
| Total assets | 604.56M | 742.30M | 796.16M | 1.24B | 1.66B | 1.33B | 2.03B | 2.26B |
| Total current liabilities | 79.73M | 85.24M | 118.81M | 135.17M | 190.24M | 225.63M | 297.53M | 468.87M |
| Short-term debt | -- | 12.26M | 12.56M | 10.14M | 8.13M | 10.64M | 12.32M | 12.81M |
| Long-term debt | 316.56M | 335.94M | 356.32M | 566.59M | 1.13B | 1.16B | 1.10B | 540.96M |
| Total liabilities | 396,290,000.00 | 480,625,000.00 | 520,271,000.00 | 833,040,000.00 | 1,568,484,000.00 | 1,661,760,000.00 | 1,739,852,000.00 | 1,525,582,000.00 |
| Total equity | 208.27M | 261.67M | 275.88M | 410.47M | 87.95M | -331.92M | 285.38M | 738.98M |
| Retained earnings | -1.28B | -1.54B | -1.83B | -2.27B | -2.70B | -3.45B | -4.36B | -5.64B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.40B | 2.08B | 1.93B | 1.79B | 1.61B | 1.63B |
| Cash & ST investments | 1.20B | 1.86B | 1.68B | 1.43B | 1.22B | 1.16B |
| Inventory | 100.71M | 107.61M | 120.97M | 132.07M | 132.91M | 142.38M |
| Total assets | 1.80B | 2.48B | 2.36B | 2.26B | 2.08B | 2.10B |
| Total current liabilities | 239.23M | 311.68M | 417.21M | 468.87M | 361.01M | 438.74M |
| Short-term debt | 6.56M | 6.66M | 7.38M | 12.81M | 8.45M | 9.82M |
| Long-term debt | 1.11B | 538.51M | 539.72M | 540.96M | 542.22M | 543.51M |
| Total liabilities | 1,703,576,000.00 | 1,230,122,000.00 | 1,415,165,000.00 | 1,525,582,000.00 | 1,371,011,000.00 | 1,345,071,000.00 |
| Total equity | 99.16M | 1.25B | 945.57M | 738.98M | 704.85M | 757.49M |
| Retained earnings | -4.62B | -4.94B | -5.31B | -5.64B | -5.80B | -5.81B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -257.98M | -250.65M | -219.35M | -363.30M | -400.44M | -536.25M | -683.88M | -935.01M |
| Depreciation & amortization | 4.83M | 10.18M | 14.15M | 14.18M | 10.33M | 10.58M | 11.01M | 16.45M |
| Free cash flow | -272.79M | -292.92M | -226.17M | -370.59M | -410.32M | -549.54M | -705.81M | -967.58M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 261.07M | 245.87M | 269.89M | 292.15M | 152.48M | 1.08B | 823.28M |
| Ending cash balance | 495.07M | 487.43M | 532.76M | 716.78M | 1.07B | 482.37M | 555.03M | 510.45M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -262.09M | -205.57M | -219.76M | -247.60M | -222.74M | -88.83M |
| Depreciation & amortization | 3.15M | 3.75M | 4.00M | 5.56M | 5.02M | 5.26M |
| Free cash flow | -272.16M | -209.05M | -222.18M | -264.19M | -226.22M | -95.09M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -256.00K | 0 | -- | -- |
| Ending cash balance | 403.25M | 1.28B | 334.76M | 510.45M | 582.19M | 544.77M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -113.92 | -108.24 | -109.42 | -126.66 | -193.22 | -- | -- | -249.28 |
| ROA %i | -60.81 | -37.77 | -38.23 | -42.62 | -33.21 | -50.20 | -54.47 | -59.53 |
| ROIC %i | -63.48 | -38.14 | -39.71 | -46.52 | -40.53 | -- | -- | -88.08 |
| 5-year avg ROE %i | -71.96 | -84.00 | -96.39 | -106.59 | -130.29 | -- | -- | -- |
| EBIT margin %i | -3,036.14 | -166.53 | -160.89 | -211.09 | -186.54 | -219.77 | -228.15 | -196.92 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.51 | 6.51 | 5.24 | 6.19 | 6.69 | 4.12 | 5.45 | 3.83 |
| Quick ratioi | 6.28 | 5.94 | 4.62 | 5.48 | 6.19 | 3.64 | 4.99 | 3.35 |
| Debt / assetsi | 52.36 | 53.49 | 50.85 | 49.24 | 71.11 | 90.54 | 56.73 | 25.91 |
| LT debt / equityi | 152.00 | 147.04 | 142.19 | 146.69 | 1,329.99 | -- | 398.26 | 77.66 |
| Interest coveragei | -11.72 | -8.64 | -9.39 | -10.31 | -20.38 | -8.80 | -10.34 | -15.39 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 167.60 | 21.60 | 22.90 | 24.50 | 35.20 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -160.54 | -165.69 | -249.28 | -294.46 | -87.22 |
| ROA %i | -68.42 | -48.22 | -53.64 | -59.53 | -61.04 | -38.20 |
| ROIC %i | -- | -63.10 | -74.68 | -88.08 | -90.03 | -52.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -243.86 | -238.74 | -246.28 | -196.92 | -134.42 | -69.73 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.86 | 6.68 | 4.63 | 3.83 | 4.47 | 3.72 |
| Quick ratioi | 5.21 | 6.13 | 4.18 | 3.35 | 3.88 | 3.14 |
| Debt / assetsi | 63.42 | 23.21 | 24.41 | 25.91 | 27.96 | 27.58 |
| LT debt / equityi | 1,146.46 | 45.52 | 60.16 | 77.66 | 81.13 | 75.26 |
| Interest coveragei | -11.61 | -11.96 | -14.09 | -15.39 | -14.39 | -10.46 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenues, net100.00%
Quote time 2026-10-08 08:22:06 · For reference only, not investment advice and not tailored to your situation.